Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Hologic

Here's What to Expect From Hologic’s Next Earnings Report

Hologic is scheduled to release its first-quarter results next month, and analysts are projecting single-digit dip in its bottom-line figure.

Barchart

Hologic Stock: Is HOLX Underperforming the Healthcare Sector?

Hologic has notably underperformed the healthcare sector over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Barchart

Hologic Stock: Analyst Estimates & Ratings

Hologic has observed a significant drop in stock prices recently and analysts are taking a more cautious stance on the company’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Preview: What To Expect From Hologic's Report

Hologic is scheduled to release its first-quarter results next month, with analysts projecting single-digit growth in its bottom line figure.

Barchart

Is Hologic Stock Underperforming the Dow?

Hologic has lagged behind the Dow index over the past three months, yet analysts remain cautiously optimistic about the stock's growth potential.

Barchart

Do Wall Street Analysts Like Hologic Stock?

Hologic has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s future.

Barchart

Hologic's Quarterly Earnings Preview: What You Need to Know

Hologic is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Hologic Stock Outperforming the Nasdaq?

Hologic has recently outperformed in the Nasdaq, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

Hologic's Q3 2024 Earnings: What to Expect

Hologic is expected to report its third-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.

Barchart

FDA Warns Of Potential Risk From Hologic Soft Tissue Devices

FDA warns of complications with Hologic's soft tissue medical devices, urging vigilance and reporting.

Top News

Dow Jones Up As Fox Skids On Tucker Carlson Exit; First Republic Dives; 3 Stocks Near Buy Points

The Dow Jones gained. Fox stock slid after Tucker Carlson left Fox News. First Republic dived on results. Microsoft stock lagged.

Investors Business Daily

Women in low-income households are less likely to receive the health care they need

Results have shown lower-earning women are less likely to receive preventative health care and more likely to give up work as a result of chronic pain

The Independent UK

Women in low-income households are less likely to access healthcare, study finds

Women in households earning up to £25k per annum are less health literate - and less likely to understand healthcare professionals

Wales Online

Sloane Stephens keen and candid about the subject of women’s health

The WTA is pushing for advancement in women’s healthcare through its partnership with Hologic

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022

Upgrades

Benzinga

Hologic's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters.

Benzinga

Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

Hologic Inc (NASDAQ:HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily drove a fall in sales. Hologic's global diagnostics business posted revenues of $987.1 million, down 7%. Diagnostics revenues excluding COVID-19 revenues…

Benzinga

Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Expert Ratings for Hologic

Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022

Upgrades

Benzinga

Death Cross Looms Over Hologic Investors

If history is any guide, there may be trouble ahead for shares of Hologic (NASDAQ:HOLX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Analyst Ratings For Hologic

Over the past 3 months, 5 analysts have published their opinion on Hologic (NASDAQ:HOLX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Looking Into Hologic's Return On Capital Employed

According to Benzinga Pro, during Q1, Hologic (NASDAQ:HOLX) earned $499.20 million, a 51.82% increase from the preceding quarter. Hologic also posted a total of $1.47 billion in sales, a 11.69% increase since Q4.

Benzinga

Hologic Q1 FY22 Sales Decline 9% On Lower COVID-19 Assay Sales; Issues Upbeat FY22 Outlook

Hologic Inc (NASDAQ: HOLX) reported

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.